|
|
||||||||
CUTTING EDGE |


Departments of
*
Microbiology and
Internal Medicine III, Kinki University School of Medicine, Osaka, Japan
| Abstract |
|---|
|
|
|---|
i signaling or divalent cations. Furthermore, we revealed consistent expression of CXCL12 (CXCR4 ligand), CXCL16 (CXCR6 ligand), and CC chemokine ligand 28 (CCR10 and CCR3 ligand) in tissues enriched with plasma cells including bone marrow, and constitutive expression of CXCL12, CXCL16, and CC chemokine ligand 28 by cultured human bone marrow stromal cells. Collectively, plasma cells are likely to be recruited to bone marrow and other target tissues via CXCR4, CXCR6, CCR10, and CCR3. CXCR6 may also contribute to tissue localization of plasma cells through its direct binding to membrane-anchored CXCL16. | Introduction |
|---|
|
|
|---|
Plasma cells represent the end stage of B cell differentiation and function as the factories for Ab production. Plasma cells from immunized mice demonstrated up-regulation of CXCR4 and down-regulation of CXCR5 and CCR7 (2, 3). Furthermore, plasma cells in chimeric mice reconstituted with CXCR4-deficient fetal liver cells were mislocalized within the spleen, found in elevated numbers in the blood, and failed to accumulate in the bone marrow (2). Thus, CXCR4 and its ligand CXC chemokine ligand (CXCL)312 play a major role in the localization of plasma cells within splenic red pulp and lymph node medullary cords as well as in the bone marrow (2). Furthermore, IgA-producing cells but not those producing IgG or IgM in mice express CCR9 and efficiently respond to its ligand CC chemokine ligand (CCL)25, which is selectively expressed by cryptic epithelial cells in the small intestine (4).
Recently, we have found that EBV-immortalized human B cells consistently up-regulate CCR6 and CCR10 and down-regulate CXCR4 and CXCR5 (5). We have further shown that the EBV-encoded latent proteins are responsible for up-regulation of CCR6 and down-regulation of CXCR4 (5). However, the up-regulation of CCR10, whose expression in normal B cells has not been reported so far (6), or the down-regulation of CXCR5 could not be explained by the effects of the EBV-encoded latent proteins (5). Because EBV-immortalized B cells resemble plasma cells, we speculated that their differentiation stages fixed by immortalization with EBV may be responsible for CCR10 up-regulation and CXCR5 down-regulation. Indeed, recent studies have consistently shown CXCR5 down-regulation in mouse plasma cells (2, 3). These considerations prompted us to examine the full repertoire of chemokine receptors expressed by human plasma cells. In this study, we report that human bone marrow plasma cells and myeloma cells selectively express CXCR4, CXCR6, CCR10, and CCR3, and that tissues known to be enriched with plasma cells as well as cultured human bone marrow stromal cells constitutively express CXCL12 (CXCR4 ligand) (7), CXCL16 (CXCR6 ligand) (8, 9), and CCL28 (CCR10 and CCR3 ligand) (10, 11).
| Materials and Methods |
|---|
|
|
|---|
RPMI8226 (JCRB0034), KMS-12BM (JCRB0429), KMS-12PE (JCRB0430), and KHM-1B (JCRB0133) were human myeloma cell lines obtained from Health Science Research Resources Bank (Sennan, Osaka, Japan). Human bone marrow irradiated stromal cells were purchased from Takara Biomedicals (Kyoto, Japan) (n = 2). Peripheral blood samples were obtained from healthy adult donors (n = 3) and patients with multiple myeloma (n = 3). Bone marrow samples were obtained from adult donors (n = 7) and also purchased from Takara Biomedicals (n = 5). Informed consents were obtained from all donors. Mononuclear cells were isolated by centrifugation on Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) and stored at -80°C until use. All human recombinant cytokines were purchased from PeproTech (Rocky Hill, NJ).
RT-PCR
This was conducted as described previously (5). cDNA samples from various human tissues were purchased from Clontech (Palo Alto, CA). Primers for the chemokine receptors and G3PDH were described previously (5). Primers for chemokines were as follows: +5'-CCCTCTGTGAGATCCGTCTTTGGCCT-3' and -5'-TCTGATTGGAACCTGAACCCCTGCTG-3' for CXCL12; +5'-CGTCACTGGAAGTTGTTATTGTGGT-3' and -5'-TGGTAGGAAGTAAATGCTTCTGGTG-3' for CXCL16; +5'-ACCACCTCTCACGCCAAAGCTCACAC-3' and -5'-CGGCACAGATATCCTTGGCCAGTTTG-3' for CCL11; +5'-CAACCTTCTGCAGCCTCCTG-3' and -5'-CCATTTTCCTTAGCATCCCA-3' for CCL27; and +5'-AGAAGCCATACTTCCCATTGC-3' and -5'-AGCTTGCACTTTCATCCACTG-3' for CCL28. Real-time PCR was performed using TaqMan assay and 7700 Sequence Detection System (Applied Biosystems, Foster City, CA). Conditions for PCR included 50°C for 2 min, 95°C for 10 min, and 50 cycles of 95°C for 15 s (denaturation) and 60°C for 1 min (annealing/extension). The primers for chemokines were as follows: +5'-CCATGCCGATTCTTCGAAAG-3' and -5'-TTCAGCCGGGCTACAATCTG-3' for CXCL12; +5'-CGCCATCGGTTCAGTTCAT-3' and -5'-ACACACGCTCCAGGAAAGGA-3' for CXCL16; and +5'-CAGAGAGGACTCGCCATCGT-3' and -5'-TGTGAAACCTCCGTGCAACA-3' for CCL28. The probes for chemokines were as follows: +5'-CATCTCAAAATTCTCAACACTCCAAACTGTGCC-3' for CXCL12; +5'-ACCATCGGTGTCTATACTACACGAGGTTCCAG-3' for CXCL16; and +5'-CTTGGCTGTCTGTGCGGCCCTACAT-3' for CCL28. The probes were labeled with reporter fluorescent dye 6-FAM at the 5' end. Primers and fluorogenic probes for G3PDH were from TaqMan kit (Applied Biosystems). Quantification of chemokine expression was obtained using sequence detector system software (Applied Biosystems).
Flow cytometric analysis
The following murine mAbs were purchased from R&D Systems (Minneapolis, MN): anti-CXCR3 (clone 49801.111), anti-CXCR6 (clone 56811.11), anti-CCR3 (clone 444.11), anti-CCR6 (clone 53103.111), anti-CXCR4 (clone 44717.111), and anti-CXCR5 (clone 51505.111). Anti-CCR7 (2H7), PE-labeled anti-CD38 (HIT2), and Cy5-labeled CD45 (HI30) were purchased from BD Biosciences (Mountain View, CA). Rabbit anti-CCR10 was purchased from BIOCARTA (San Diego, CA). Isotype controls were purchased from DAKO (Kyoto, Japan). Cells were washed with PBS containing 2% FBS and reacted for 30 min with each mAb. After washing, cells were reacted with FITC-conjugated sheep (F(ab')2) anti-mouse IgG (Sigma-Aldrich, St. Louis, MO). In some experiments, cells were double stained with PE-labeled anti-CD38 and Cy5-labeled anti-CD45. For intracellular staining of CCR10, cells fixed and permeabilized with 2% paraformaldehyde and 0.1% Triton X-100 were indirectly stained with anti-CCR10 and FITC-labeled goat anti-rabbit IgG (Sigma-Aldrich). After staining, cells were analyzed on FACSCalibur (BD Biosciences) with appropriate gatings and quantitated in comparison with isotype control Abs. Dead cells were gated out by staining with propidium iodide.
Chemotaxis assay
All recombinant chemokines were purchased from R&D Systems. Migration assays for fresh human bone marrow mononuclear cells were conducted using Transwell plates with 8-µm pore size (Corning, Corning, NY) as described previously (5).
Cell adhesion assays
Cell adhesion to immobilized fibronectin was determined as described previously (12). The extracellular domain of human CXCL16/SR-PSOX (13) was subcloned into pDREF-SEAP (His)6-Hyg expression vector (14), and CXCL16 fused at the C terminus with secreted form of placental alkaline phosphatase (SEAP), or CXCL16-SEAP, was generated by transfection to HEK293 cells. Cell adhesion to immobilized CXCL16 was determined essentially as described previously (14).
ELISA
Human bone marrow stromal cells were seeded in 24-well plates at a density of 1 x 105 cells/well and cultured without or with 10 ng/ml IL-1
. Measurement of CXCL12 and CCL28 in the culture supernatants was conducted using ELISA kits purchased from R&D Systems. For standardization of assay, serially diluted recombinant CXCL12 or CCL28 was included in each ELISA plate.
| Results |
|---|
|
|
|---|
To gain an insight into the full repertoire of chemokine receptors expressed by human plasma cells, we first examined chemokine receptor expression in a panel of four human myeloma cell lines. RT-PCR analysis using specific primer sets for all known 18 chemokine receptors (CXCR1
6, CCR1
10, XCR1, and CX3CR1) (1) revealed that the myeloma cell lines were consistently positive for CXCR4, CXCR6, CCR10, and CCR3. Staining of these myeloma cell lines with specific Abs for various chemokine receptors and flow cytometric analysis verified the RT-PCR results (data not shown).
After getting a consensus profile of chemokine receptor expression in human myeloma cell lines, we proceeded to examine the expression of selected chemokine receptors on human bone marrow plasma cells. Plasma cells in bone marrow mononuclear cells could be identified by the expression of high levels of CD38 on their surface (15, 16). We confirmed that CD38high cells sorted from bone marrow mononuclear cells had the typical plasma cell morphology (Fig. 1a). As shown in Fig. 1a, plasma cells in the bone marrow expressed CXCR4 and CXCR6 at high levels, CCR10 at intermediate levels, CCR3 at low levels, and CXCR5, CCR6, and CCR7 at marginal levels. We found no significant differences in the expression levels of these chemokine receptors between CD38highCD45+ immature and CD38highCD45- mature plasma cells (15, 16) (data not shown).
|
Responses of plasma cells to the ligands of CXCR4, CXCR6, CCR10, and CCR3
We next examined chemotactic responses of bone marrow plasma cells to CXCL12 (CXCR4 ligand), CXCL13 (CXCR5 ligand), CXCL16 (CXCR6 ligand), CCL11 (CCR3 ligand), CCL27 (CCR10 ligand), and CCL28 (CCR10 and CCR3 ligand) (1). As shown in Fig. 2a, CXCL12, CXCL16, and CCL28 induced migration of plasma cells with similar potencies and efficiencies. CCL11 and CCL27 also induced modest migratory responses, while CXCL13 induced only marginal responses. The chemotactic responses of plasma cells to CCL28, which signals via both CCR10 and CCR3 (10, 11), were roughly about the summation of those to CCL27 and CCL11, the specific ligands of CCR10 and CCR3, respectively (1). These results were in good accordance with the expression profile of chemokine receptors on plasma cells (Fig. 1).
|
4 integrin mAb to block cell adhesion to fibronectin. Direct adhesion of plasma cells to immobilized CXCL16
CXCL16, the ligand of CXCR6, is a novel transmembrane-type chemokine whose structure is very similar to that of another transmembrane chemokine fractalkine/CX3C chemokine ligand (CX3CL)1 (8, 9). Previously, we have shown that immobilized CX3CL1 induces firm adhesion of CX3CR1-expressing cells via its chemokine domain in both static and flow conditions without requiring signaling via G
i or divalent cations (14, 17). The structural similarity of CXCL16 to CX3CL1 prompted us to examine whether immobilized CXCL16 was also capable of inducing direct adhesion of plasma cells expressing CXCR6. As shown in Fig. 2c, CXCL16-SEAP immobilized to the plastic surface efficiently induced adhesion of plasma cells, which was effectively blocked by anti-CXCR6 but not by control Ab. Furthermore, pretreatment of plasma cells with pertussis toxin or presence of EGTA during the binding assay did not affect the levels of adhesion. Collectively, immobilized CXCL16 was indeed capable of inducing adhesion of plasma cells via CXCR6 without requiring signaling via G
i or divalent cations (integrins).
Expression of CXCL12, CXCL16, and CCL28 by human bone marrow stromal cells
The selective expression of CXCR4, CXCR6, CCR10, and CCR3 by bone marrow plasma cells suggests that their respective chemokine ligands may be involved in the homing and tissue microenvironmental localization of plasma cells in the bone marrow and other target tissues. However, except for CXCL12 (CXCR4 ligand) (7), expression of these chemokines in the bone marrow has not been reported. Therefore, we conducted RT-PCR analysis for expression of these chemokines in bone marrow and other human tissues known to be enriched with plasma cells. As shown in Fig. 3a, all the tissues examined including bone marrow expressed CXCL12 (CXCR4 ligand), CXCL16 (CXCR6 ligand), and CCL28 (CCR10 and CCR3 ligand) at high levels. Thus, these chemokines can be collectively involved in the homing and localization of plasma cells in the bone marrow and other target tissues. In contrast, CCL11 (CCR3 ligand) or CCL27 (CCR10 ligand) was hardly expressed in the bone marrow.
|
, TNF-
, or IFN-
, while that of CXCL16 was enhanced by IFN-
. In contrast, the expression of CCL28 was hardly affected by any cytokines. We also examined secretion of CXCL12 and CCL28 by bone marrow stromal cells. As shown in Fig. 3c, stromal cells indeed secreted copious amounts of CXCL12 and CCL28 in the culture supernatants. Consistent with the results from RT-PCR (Fig. 3b), treatment of stromal cells with IL-1
significantly enhanced secretion of CXCL12 (p < 0.05) but not that of CCL28. | Discussion |
|---|
|
|
|---|
CXCL16 is a novel transmembrane-type chemokine (8, 9), which was also identified as a novel scavenger receptor for oxidized low density lipoprotein (13). In the present study, we have shown that immobilized CXCL16 is capable of inducing adhesion of plasma cells expressing CXCR6 without requiring G
i-mediated signaling or divalent cations (Fig. 2), an observation quite similar to that of another transmembrane-type chemokine CX3CL1 (14, 17). Thus, like CX3CL1, CXCL16 may function as a chemoattractant in its soluble form and a cell adhesion molecule in its membrane-anchored form. This may allow CXCL16 to contribute to plasma cell localization in the bone marrow and other target tissues not only by its chemotactic activity but also by its direct cell adhering activity.
In conclusion, we have shown for the first time that human bone marrow plasma cells and myeloma cells consistently express CXCR6, CCR10, and CCR3 besides CXCR4. The important role of CXCR4 in migration and tissue localization of plasma cells has been reported previously (2). Thus, the exact roles of CXCR6, CCR10, and CCR3 in the migration and tissue localization of plasma cells remain to be seen. It also remains to be seen whether human plasma cells producing different Ig isotypes express a different set of chemokine receptors to migrate to different anatomical sites as mouse plasma cells do (4).
| Acknowledgments |
|---|
| Footnotes |
|---|
2 Address correspondence to Dr. Osamu Yoshie, Department of Microbiology, Kinki University School of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Osaka 589-8511, Japan. E-mail address: o.yoshie{at}med.kindai.ac.jp ![]()
3 Abbreviations used in this paper: CXCL, CXC chemokine ligand; CCL, CC chemokine ligand; CX3CL, CX3C chemokine ligand; VLA-4, very late Ag-4; SEAP, secreted form of placental alkaline phosphatase. ![]()
Received for publication October 8, 2002. Accepted for publication November 27, 2002.
| References |
|---|
|
|
|---|
modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood 97:346.This article has been cited by other articles:
![]() |
P. Gutwein, M. S. Abdel-Bakky, A. Schramme, K. Doberstein, N. Kampfer-Kolb, K. Amann, I. A. Hauser, N. Obermuller, C. Bartel, A.-A. H. Abdel-Aziz, et al. CXCL16 Is Expressed in Podocytes and Acts as a Scavenger Receptor for Oxidized Low-Density Lipoprotein Am. J. Pathol., June 1, 2009; 174(6): 2061 - 2072. [Abstract] [Full Text] [PDF] |
||||
![]() |
A W T van Lieshout, R van der Voort, L W J Toonen, S F G van Helden, C G Figdor, P L C M van Riel, T R D J Radstake, and G J Adema Regulation of CXCL16 expression and secretion by myeloid cells is not altered in rheumatoid arthritis Ann Rheum Dis, June 1, 2009; 68(6): 1036 - 1043. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Azab, J. M. Runnels, C. Pitsillides, A.-S. Moreau, F. Azab, X. Leleu, X. Jia, R. Wright, B. Ospina, A. L. Carlson, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy Blood, April 30, 2009; 113(18): 4341 - 4351. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wang, Y. Lu, J. Wang, A. E. Koch, J. Zhang, and R. S. Taichman CXCR6 Induces Prostate Cancer Progression by the AKT/Mammalian Target of Rapamycin Signaling Pathway Cancer Res., December 15, 2008; 68(24): 10367 - 10377. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Airoldi, C. Cocco, N. Giuliani, M. Ferrarini, S. Colla, E. Ognio, G. Taverniti, E. Di Carlo, G. Cutrona, V. Perfetti, et al. Constitutive expression of IL-12R{beta}2 on human multiple myeloma cells delineates a novel therapeutic target Blood, August 1, 2008; 112(3): 750 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Lu, J. Wang, Y. Xu, A. E. Koch, Z. Cai, X. Chen, D. L. Galson, R. S. Taichman, and J. Zhang CXCL16 Functions as a Novel Chemotactic Factor for Prostate Cancer Cells In vitro Mol. Cancer Res., April 1, 2008; 6(4): 546 - 554. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. J. de Gorter, R. M. Reijmers, E. A. Beuling, H. P. H. Naber, A. Kuil, M. J. Kersten, S. T. Pals, and M. Spaargaren The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells Blood, April 1, 2008; 111(7): 3364 - 3372. [Abstract] [Full Text] [PDF] |
||||
![]() |
A.-K. Shirakawa, D. Nagakubo, K. Hieshima, T. Nakayama, Z. Jin, and O. Yoshie 1,25-Dihydroxyvitamin D3 Induces CCR10 Expression in Terminally Differentiating Human B Cells J. Immunol., March 1, 2008; 180(5): 2786 - 2795. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Leleu, X. Jia, J. Runnels, H. T. Ngo, A.-S. Moreau, M. Farag, J. A. Spencer, C. M. Pitsillides, E. Hatjiharissi, A. Roccaro, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia Blood, December 15, 2007; 110(13): 4417 - 4426. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. T. Pals, D. J. J. de Gorter, and M. Spaargaren Lymphoma dissemination: the other face of lymphocyte homing Blood, November 1, 2007; 110(9): 3102 - 3111. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Galkina, B. L. Harry, A. Ludwig, E. A. Liehn, J. M. Sanders, A. Bruce, C. Weber, and K. Ley CXCR6 Promotes Atherosclerosis by Supporting T-Cell Homing, Interferon-{gamma} Production, and Macrophage Accumulation in the Aortic Wall Circulation, October 16, 2007; 116(16): 1801 - 1811. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W T van Lieshout, J. Fransen, M. Flendrie, A. M M Eijsbouts, F. H J van den Hoogen, P. L C M van Riel, and T. R D J Radstake Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis Ann Rheum Dis, October 1, 2007; 66(10): 1334 - 1338. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muehlenbachs, M. Fried, J. Lachowitzer, T. K. Mutabingwa, and P. E. Duffy Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection J. Immunol., July 1, 2007; 179(1): 557 - 565. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Koedel, U. M. Merbt, C. Schmidt, B. Angele, B. Popp, H. Wagner, H.-W. Pfister, and C. J. Kirschning Acute Brain Injury Triggers MyD88-Dependent, TLR2/4-Independent Inflammatory Responses Am. J. Pathol., July 1, 2007; 171(1): 200 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Alsayed, H. Ngo, J. Runnels, X. Leleu, U. K. Singha, C. M. Pitsillides, J. A. Spencer, T. Kimlinger, J. M. Ghobrial, X. Jia, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma Blood, April 1, 2007; 109(7): 2708 - 2717. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Nadav, B.-Z. Katz, S. Baron, N. Cohen, E. Naparstek, and B. Geiger The Generation and Regulation of Functional Diversity of Malignant Plasma Cells. Cancer Res., September 1, 2006; 66(17): 8608 - 8616. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Feng, M. C. Jaimes, N. H. Lazarus, D. Monak, C. Zhang, E. C. Butcher, and H. B. Greenberg Redundant Role of Chemokines CCL25/TECK and CCL28/MEC in IgA+ Plasmablast Recruitment to the Intestinal Lamina Propria After Rotavirus Infection J. Immunol., May 15, 2006; 176(10): 5749 - 5759. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Huang, X.-Y. Zhu, M.-R. Du, X. Wu, M.-Y. Wang, and D.-J. Li Chemokine CXCL16, a scavenger receptor, induces proliferation and invasion of first-trimester human trophoblast cells in an autocrine manner Hum. Reprod., April 1, 2006; 21(4): 1083 - 1091. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Burger and T. J. Kipps CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment Blood, March 1, 2006; 107(5): 1761 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hase, T. Murakami, H. Takatsu, T. Shimaoka, M. Iimura, K. Hamura, K. Kawano, S. Ohshima, R. Chihara, K. Itoh, et al. The Membrane-Bound Chemokine CXCL16 Expressed on Follicle-Associated Epithelium and M Cells Mediates Lympho-Epithelial Interaction in GALT J. Immunol., January 1, 2006; 176(1): 43 - 51. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Sordi, M. L. Malosio, F. Marchesi, A. Mercalli, R. Melzi, T. Giordano, N. Belmonte, G. Ferrari, B. E. Leone, F. Bertuzzi, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets Blood, July 15, 2005; 106(2): 419 - 427. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Xu, W. Xu, Y. Chu, Y. Gong, Z. Jiang, and S. Xiong Involvement of Up-Regulated CXC Chemokine Ligand 16/Scavenger Receptor That Binds Phosphatidylserine and Oxidized Lipoprotein in Endotoxin-Induced Lethal Liver Injury via Regulation of T-Cell Recruitment and Adhesion Infect. Immun., July 1, 2005; 73(7): 4007 - 4016. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. H. A. Rayes, A. C. Rawstron, G. J. Morgan, and F. E. Davies The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells Blood, June 15, 2005; 105(12): 4895 - 4896. [Full Text] [PDF] |
||||
![]() |
G. Muehlinghaus, L. Cigliano, S. Huehn, A. Peddinghaus, H. Leyendeckers, A. E. Hauser, F. Hiepe, A. Radbruch, S. Arce, and R. A. Manz Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells Blood, May 15, 2005; 105(10): 3965 - 3971. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. T. Avery, J. I. Ellyard, F. Mackay, L. M. Corcoran, P. D. Hodgkin, and S. G. Tangye Increased Expression of CD27 on Activated Human Memory B Cells Correlates with Their Commitment to the Plasma Cell Lineage J. Immunol., April 1, 2005; 174(7): 4034 - 4042. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. C.W. Zannettino, A. N. Farrugia, A. Kortesidis, J. Manavis, L. B. To, S. K. Martin, P. Diamond, H. Tamamura, T. Lapidot, N. Fujii, et al. Elevated Serum Levels of Stromal-Derived Factor-1{alpha} Are Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients Cancer Res., March 1, 2005; 65(5): 1700 - 1709. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sato, H. Thorlacius, B. Johnston, T. L. Staton, W. Xiang, D. R. Littman, and E. C. Butcher Role for CXCR6 in Recruitment of Activated CD8+ Lymphocytes to Inflamed Liver J. Immunol., January 1, 2005; 174(1): 277 - 283. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. F. Charo and M. B. Taubman Chemokines in the Pathogenesis of Vascular Disease Circ. Res., October 29, 2004; 95(9): 858 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Jaimes, O. L. Rojas, E. J. Kunkel, N. H. Lazarus, D. Soler, E. C. Butcher, D. Bass, J. Angel, M. A. Franco, and H. B. Greenberg Maturation and Trafficking Markers on Rotavirus-Specific B Cells during Acute Infection and Convalescence in Children J. Virol., October 15, 2004; 78(20): 10967 - 10976. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kukita, N. Wada, A. Kukita, T. Kakimoto, F. Sandra, K. Toh, K. Nagata, T. Iijima, M. Horiuchi, H. Matsusaki, et al. RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis J. Exp. Med., October 4, 2004; 200(7): 941 - 946. [Abstract] [Full Text] [PDF] |
||||
![]() |
J J Haringman, J Ludikhuize, and P P Tak Chemokines in joint disease: the key to inflammation? Ann Rheum Dis, October 1, 2004; 63(10): 1186 - 1194. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Wilson and E. C. Butcher CCL28 Controls Immunoglobulin (Ig)A Plasma Cell Accumulation in the Lactating Mammary Gland and IgA Antibody Transfer to the Neonate J. Exp. Med., September 20, 2004; 200(6): 805 - 809. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hieshima, Y. Kawasaki, H. Hanamoto, T. Nakayama, D. Nagakubo, A. Kanamaru, and O. Yoshie CC Chemokine Ligands 25 and 28 Play Essential Roles in Intestinal Extravasation of IgA Antibody-Secreting Cells J. Immunol., September 15, 2004; 173(6): 3668 - 3675. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. V. Gulino, D. Moratto, S. Sozzani, P. Cavadini, K. Otero, L. Tassone, L. Imberti, S. Pirovano, L. D. Notarangelo, R. Soresina, et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome Blood, July 15, 2004; 104(2): 444 - 452. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Abel, C. Hundhausen, R. Mentlein, A. Schulte, T. A. Berkhout, N. Broadway, D. Hartmann, R. Sedlacek, S. Dietrich, B. Muetze, et al. The Transmembrane CXC-Chemokine Ligand 16 Is Induced by IFN-{gamma} and TNF-{alpha} and Shed by the Activity of the Disintegrin-Like Metalloproteinase ADAM10 J. Immunol., May 15, 2004; 172(10): 6362 - 6372. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Daoudi, E. Lavergne, A. Garin, N. Tarantino, P. Debre, F. Pincet, C. Combadiere, and P. Deterre Enhanced Adhesive Capacities of the Naturally Occurring Ile249-Met280 Variant of the Chemokine Receptor CX3CR1 J. Biol. Chem., May 7, 2004; 279(19): 19649 - 19657. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Hanamoto, T. Nakayama, H. Miyazato, S. Takegawa, K. Hieshima, Y. Tatsumi, A. Kanamaru, and O. Yoshie Expression of CCL28 by Reed-Sternberg Cells Defines a Major Subtype of Classical Hodgkin's Disease with Frequent Infiltration of Eosinophils and/or Plasma Cells Am. J. Pathol., March 1, 2004; 164(3): 997 - 1006. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Nakayama, K. Hieshima, D. Nagakubo, E. Sato, M. Nakayama, K. Kawa, and O. Yoshie Selective Induction of Th2-Attracting Chemokines CCL17 and CCL22 in Human B Cells by Latent Membrane Protein 1 of Epstein-Barr Virus J. Virol., February 15, 2004; 78(4): 1665 - 1674. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Shimaoka, T. Nakayama, N. Fukumoto, N. Kume, S. Takahashi, J. Yamaguchi, M. Minami, K. Hayashida, T. Kita, J. Ohsumi, et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells J. Leukoc. Biol., February 1, 2004; 75(2): 267 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Chandrasekar, S. Bysani, and S. Mummidi CXCL16 Signals via Gi, Phosphatidylinositol 3-Kinase, Akt, I{kappa}B Kinase, and Nuclear Factor-{kappa}B and Induces Cell-Cell Adhesion and Aortic Smooth Muscle Cell Proliferation J. Biol. Chem., January 30, 2004; 279(5): 3188 - 3196. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ueda, K. Yang, S. J. Foster, M. Kondo, and G. Kelsoe Inflammation Controls B Lymphopoiesis by Regulating Chemokine CXCL12 Expression J. Exp. Med., January 5, 2004; 199(1): 47 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. H. Underhill, K. P. Kolli, and G. S. Kansas Complexity within the plasma cell compartment of mice deficient in both E- and P-selectin: implications for plasma cell differentiation Blood, December 1, 2003; 102(12): 4076 - 4083. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |